Esophageal carcinoma is a heterogeneous epithelial malignancy of the esophagus comprising two biologically and epidemiologically distinct histologic subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC dominates globally and is concentrated in East Asia, parts of Africa, and along the "esophageal cancer belt", and is driven largely by tobacco, alcohol, and other carcinogenic environmental exposures acting on stratified squamous mucosa. EAC predominates in Western populations, arises almost exclusively from Barrett metaplasia in the setting of chronic gastroesophageal reflux and obesity, and resembles chromosomally unstable gastric adenocarcinoma molecularly. Both subtypes typically present late with dysphagia and weight loss, carry a poor prognosis, and are managed with multimodality regimens combining surgery, chemoradiotherapy, and PD-1-directed immunotherapy.
Ask a research question about Esophageal Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Esophageal Carcinoma
creation_date: "2026-05-13T00:00:00Z"
updated_date: "2026-05-13T12:00:00Z"
description: >-
Esophageal carcinoma is a heterogeneous epithelial malignancy of the esophagus
comprising two biologically and epidemiologically distinct histologic
subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal
adenocarcinoma (EAC). ESCC dominates globally and is concentrated in East
Asia, parts of Africa, and along the "esophageal cancer belt", and is driven
largely by tobacco, alcohol, and other carcinogenic environmental exposures
acting on stratified squamous mucosa. EAC predominates in Western populations,
arises almost exclusively from Barrett metaplasia in the setting of chronic
gastroesophageal reflux and obesity, and resembles chromosomally unstable
gastric adenocarcinoma molecularly. Both subtypes typically present late with
dysphagia and weight loss, carry a poor prognosis, and are managed with
multimodality regimens combining surgery, chemoradiotherapy, and
PD-1-directed immunotherapy.
category: Complex
categories:
- Gastrointestinal Cancer
- Esophageal Cancer
- Solid Tumor
parents:
- esophageal cancer
- carcinoma
disease_term:
preferred_term: esophageal carcinoma
term:
id: MONDO:0019086
label: carcinoma of esophagus
has_subtypes:
- name: ESCC
display_name: Esophageal Squamous Cell Carcinoma
description: >-
Squamous-cell histology arising from the stratified squamous mucosa of the
esophagus. Dominant subtype worldwide; strongly linked to tobacco, alcohol,
and other environmental carcinogens; molecularly characterized by frequent
TP53 loss-of-function and recurrent alterations in cell-cycle, squamous
differentiation, NOTCH, and PI3K/AKT pathways.
classification: histologic
evidence:
- reference: PMID:28052061
reference_title: Integrated genomic characterization of oesophageal carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Beyond known histopathological and epidemiologic distinctions, molecular features differentiated oesophageal squamous cell carcinomas from oesophageal adenocarcinomas."
explanation: TCGA shows ESCC and EAC are molecularly distinct, supporting the histologic-subtype dichotomy.
- name: EAC
display_name: Esophageal Adenocarcinoma
description: >-
Gland-forming malignancy arising in the distal esophagus from Barrett
metaplastic mucosa after chronic gastroesophageal reflux. Western-population
predominant; characterized by chromosomal instability, near-universal TP53
alteration, and a targetable ERBB2-amplified subset.
classification: histologic
evidence:
- reference: PMID:34503107
reference_title: Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Barrett's esophagus (BE), a metaplastic response of the esophagus to gastro-esophageal reflux disease, is the main risk factor for the development of EAC. Almost all EACs are derived from BE."
explanation: Confirms EAC almost universally arises from Barrett metaplasia driven by chronic GERD.
pathophysiology:
- name: ESCC Carcinogen-Driven Squamous Transformation
description: >-
In esophageal squamous cell carcinoma, chronic exposure of stratified
squamous epithelium to tobacco-derived carcinogens and acetaldehyde from
alcohol metabolism produces DNA damage and mutational burden that selects
for TP53 loss-of-function and recurrent alterations in cell-cycle, squamous
differentiation, and NOTCH signaling.
cell_types:
- preferred_term: epithelial cell of esophagus
term:
id: CL:0002252
label: epithelial cell of esophagus
biological_processes:
- preferred_term: DNA repair
modifier: DECREASED
term:
id: GO:0006281
label: DNA repair
locations:
- preferred_term: esophagus
term:
id: UBERON:0001043
label: esophagus
evidence:
- reference: PMID:20224883
reference_title: "Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Both alcohol consumption and cigarette smoking are major risk factors for the development of ESCC."
explanation: Identifies tobacco and alcohol as principal upstream drivers of ESCC carcinogenesis.
- reference: PMID:28052061
reference_title: Integrated genomic characterization of oesophageal carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Squamous cell carcinomas showed frequent genomic amplifications of CCND1 and SOX2 and/or TP63, whereas ERBB2, VEGFA and GATA4 and GATA6 were more commonly amplified in adenocarcinomas."
explanation: Supports distinct ESCC genomic landscape with squamous-lineage transcription-factor amplifications.
downstream:
- target: Adaptive Immune Resistance
description: Expanding ESCC tumors acquire PD-L1-linked checkpoint programs that enable immune escape.
- target: Dysphagia
description: Tumor growth progressively narrows the esophageal lumen and impairs swallowing.
- target: Weight Loss
description: Tumor burden and impaired oral intake contribute to weight loss.
- name: Barrett Metaplasia to EAC Sequence
description: >-
In esophageal adenocarcinoma, chronic gastroesophageal reflux drives
columnar (Barrett) metaplasia of the distal esophageal mucosa, which
progresses through dysplasia to invasive adenocarcinoma. The transition is
accompanied by progressive TP53 inactivation and accumulating chromosomal
instability with recurrent copy-number changes including ERBB2
amplification.
cell_types:
- preferred_term: epithelial cell of esophagus
term:
id: CL:0002252
label: epithelial cell of esophagus
biological_processes:
- preferred_term: epithelial cell differentiation
modifier: ABNORMAL
term:
id: GO:0030855
label: epithelial cell differentiation
locations:
- preferred_term: esophagus
term:
id: UBERON:0001043
label: esophagus
evidence:
- reference: PMID:40874980
reference_title: "Screening for Barrett Esophagus and Esophageal Adenocarcinoma: Approaches and Outcomes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Barrett esophagus (BE) is the only known histological precursor to esophageal adenocarcinoma (EAC)."
explanation: Establishes Barrett esophagus as the obligate precursor lesion of EAC.
- reference: PMID:34503107
reference_title: Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The tumor suppressor gene TP53 is mutated in 70 to 80% of tumors followed by genomic alterations in CDKN2A, KRAS, ERBB2, ARID1A, SMAD4 and a long tail of less frequently mutated genes."
explanation: Anchors recurrent TP53/CDKN2A/ERBB2 lesions as the molecular backbone of the Barrett-EAC progression.
downstream:
- target: Barrett Esophagus (Precursor Lesion)
description: Columnar (Barrett) metaplasia of the distal esophageal mucosa is the obligate histologic precursor of EAC.
- target: Adaptive Immune Resistance
description: Invasive EAC subsets acquire PD-L1-linked checkpoint programs that enable immune escape.
- target: Dysphagia
description: Tumor growth progressively narrows the esophageal lumen and impairs swallowing.
- target: Weight Loss
description: Tumor burden and impaired oral intake contribute to weight loss.
- name: Adaptive Immune Resistance
conforms_to: "immune_checkpoint_blockade#Adaptive Immune Resistance"
description: >-
A clinically meaningful subset of advanced esophageal carcinoma (both ESCC
and EAC, including Barrett-associated dysplastic and invasive lesions)
expresses PD-L1 on tumor cells and tumor-infiltrating immune cells,
consistent with a checkpoint-mediated adaptive immune-resistance state
targetable with PD-1 blockade.
biological_processes:
- preferred_term: negative regulation of T cell mediated immunity
modifier: INCREASED
term:
id: GO:0002710
label: negative regulation of T cell mediated immunity
evidence:
- reference: PMID:30684971
reference_title: "PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "PD-L1 was expressed on 29.9% (113/378) ESCC tumor cells and 40.2% (152/378) tumor-infiltrating immune cells."
explanation: Documents a PD-L1-positive checkpoint immune-evasion state in advanced ESCC.
- reference: PMID:31724072
reference_title: "PD-L1 expression in gastroesophageal dysplastic lesions."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "A higher prevalence of PD-L1-positive cases was observed among esophageal specimens compared with gastric ones (p = 0.0003), in high-grade and adenocarcinoma samples in comparison with low-grade dysplasia (p < 0.0001), and in lesions with mismatch repair deficiency (p = 0.028)."
explanation: Supports PD-L1 pathway activation extending across Barrett-associated dysplastic and adenocarcinoma lesions.
phenotypes:
- name: Dysphagia
description: Progressive difficulty swallowing solids, then liquids, is the most common presenting symptom of esophageal carcinoma due to luminal narrowing by tumor.
phenotype_term:
preferred_term: Dysphagia
term:
id: HP:0002015
label: Dysphagia
- name: Weight Loss
description: Unintentional weight loss is a frequent presenting feature, reflecting both impaired oral intake from dysphagia and cancer cachexia.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
- name: Odynophagia
description: Painful swallowing can occur with ulcerated or locally invasive esophageal tumors.
phenotype_term:
preferred_term: Odynophagia
term:
id: HP:0032043
label: Odynophagia
- name: Hematemesis
description: Bleeding from ulcerated esophageal tumor can manifest as hematemesis, particularly with advanced or invasive disease.
phenotype_term:
preferred_term: Hematemesis
term:
id: HP:0002248
label: Hematemesis
environmental:
- name: Tobacco Smoking
description: >-
Cigarette smoking is a major modifiable risk factor, especially for ESCC,
exposing the esophageal epithelium to carcinogens that cooperate with
alcohol in upper aerodigestive carcinogenesis.
effect: HARMFUL
exposure_term:
preferred_term: exposure to tobacco smoking
term:
id: ECTO:6000029
label: exposure to tobacco smoking
evidence:
- reference: PMID:20224883
reference_title: "Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Both alcohol consumption and cigarette smoking are major risk factors for the development of ESCC."
explanation: Identifies cigarette smoking as a major ESCC risk factor.
- name: Alcohol Consumption
description: >-
Alcohol use is a major risk factor for ESCC and acts synergistically with
tobacco, with acetaldehyde and ALDH2-dependent susceptibility contributing
to mutational burden in esophageal squamous epithelium.
effect: HARMFUL
exposure_term:
preferred_term: exposure to ethanol
term:
id: ECTO:9000027
label: exposure to ethanol
evidence:
- reference: PMID:20224883
reference_title: "Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Acetaldehyde is the most toxic ethanol metabolite in alcohol-associated carcinogenesis"
explanation: Identifies acetaldehyde from ethanol metabolism as the proximate carcinogenic mediator.
- name: Chronic Gastroesophageal Reflux Disease
description: >-
Chronic GERD drives Barrett metaplasia of the distal esophagus and is the
principal modifiable upstream exposure for esophageal adenocarcinoma.
effect: HARMFUL
evidence:
- reference: PMID:34503107
reference_title: Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Barrett's esophagus (BE), a metaplastic response of the esophagus to gastro-esophageal reflux disease, is the main risk factor for the development of EAC. Almost all EACs are derived from BE."
explanation: Identifies chronic GERD-driven Barrett metaplasia as the principal upstream risk factor for EAC.
- name: Western Lifestyle / Obesity
description: >-
Rising obesity prevalence in Western nations is a principal driver of the
epidemiologic shift toward EAC predominance over ESCC.
effect: HARMFUL
evidence:
- reference: PMID:37812328
reference_title: "Esophageal Cancer: Overview, Risk Factors, and Reasons for the Rise."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In Western nations, more often the United States, there has been a shift from SCC predominance to the majority of new cases of EC being adenocarcinoma. This shift within the United States has largely correlated with a rise in obesity."
explanation: Anchors the histology shift to a population-level obesity trend.
genetic:
- name: TP53
gene_term:
preferred_term: TP53
term:
id: hgnc:11998
label: TP53
association: Somatic Loss-of-Function Mutation
evidence:
- reference: PMID:34503107
reference_title: Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The tumor suppressor gene TP53 is mutated in 70 to 80% of tumors followed by genomic alterations in CDKN2A, KRAS, ERBB2, ARID1A, SMAD4 and a long tail of less frequently mutated genes."
explanation: Identifies TP53 as the dominant recurrent somatic alteration in EAC; comparable predominance is well-documented in ESCC.
notes: >-
Somatic TP53 loss-of-function is the most common recurrent driver event in
both EAC and ESCC and is closely tied to chromosomal instability across the
Barrett-dysplasia-adenocarcinoma sequence.
- name: CDKN2A
gene_term:
preferred_term: CDKN2A
term:
id: hgnc:1787
label: CDKN2A
association: Recurrent Somatic Alteration
evidence:
- reference: PMID:34503107
reference_title: Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The tumor suppressor gene TP53 is mutated in 70 to 80% of tumors followed by genomic alterations in CDKN2A, KRAS, ERBB2, ARID1A, SMAD4 and a long tail of less frequently mutated genes."
explanation: Supports CDKN2A as a recurrent somatic alteration disrupting cell-cycle control in esophageal carcinoma.
- name: ERBB2 (HER2)
gene_term:
preferred_term: ERBB2
term:
id: hgnc:3430
label: ERBB2
association: Somatic Amplification
evidence:
- reference: PMID:28052061
reference_title: Integrated genomic characterization of oesophageal carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Squamous cell carcinomas showed frequent genomic amplifications of CCND1 and SOX2 and/or TP63, whereas ERBB2, VEGFA and GATA4 and GATA6 were more commonly amplified in adenocarcinomas."
explanation: Supports ERBB2 amplification as a recurrent EAC-predominant driver and biomarker for HER2-directed therapy.
notes: >-
ERBB2 amplification defines a clinically actionable subset of EAC eligible
for HER2-directed therapy.
histopathology:
- name: Barrett Esophagus (Precursor Lesion)
description: >-
Specialized intestinal metaplasia of the distal esophageal mucosa replacing
stratified squamous epithelium with columnar epithelium containing goblet
cells. The obligate histologic precursor of esophageal adenocarcinoma.
subtype: EAC
evidence:
- reference: PMID:40874980
reference_title: "Screening for Barrett Esophagus and Esophageal Adenocarcinoma: Approaches and Outcomes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Barrett esophagus (BE) is the only known histological precursor to esophageal adenocarcinoma (EAC)."
explanation: Defines Barrett esophagus as the histologic precursor lesion specific to the EAC subtype.
treatments:
- name: Esophagectomy
description: >-
Surgical resection of the esophagus remains the cornerstone of curative
treatment for resectable invasive esophageal carcinoma, typically combined
with neoadjuvant chemoradiotherapy.
treatment_term:
preferred_term: esophagectomy
term:
id: MAXO:0001052
label: esophagectomy
evidence:
- reference: PMID:28648400
reference_title: Oesophageal cancer.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Neoadjuvant therapy with \nchemotherapy or chemoradiotherapy has supplemented surgery as standard treatment \nof locally advanced oesophageal cancer."
explanation: Supports surgery (esophagectomy) plus neoadjuvant therapy as the standard curative-intent platform.
- name: Neoadjuvant Chemoradiotherapy
description: >-
Combined chemotherapy and radiation given prior to esophagectomy improves
long-term survival in locally advanced resectable esophageal carcinoma.
treatment_term:
preferred_term: chemoradiotherapy
term:
id: NCIT:C94626
label: Chemoradiotherapy
therapeutic_agent:
- preferred_term: cisplatin
term:
id: CHEBI:27899
label: cisplatin
- preferred_term: fluorouracil
term:
id: CHEBI:46345
label: 5-fluorouracil
evidence:
- reference: PMID:28648400
reference_title: Oesophageal cancer.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Neoadjuvant therapy with \nchemotherapy or chemoradiotherapy has supplemented surgery as standard treatment \nof locally advanced oesophageal cancer."
explanation: Establishes neoadjuvant chemoradiotherapy as standard of care for locally advanced esophageal carcinoma.
- name: First-Line Pembrolizumab Plus Chemotherapy
description: >-
Adding the anti-PD-1 antibody pembrolizumab to first-line
fluoropyrimidine-platinum chemotherapy improves overall and
progression-free survival in advanced esophageal carcinoma, with the
largest benefit in ESCC and in PD-L1 CPS-high disease.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: pembrolizumab
term:
id: NCIT:C106432
label: Pembrolizumab
- preferred_term: cisplatin
term:
id: CHEBI:27899
label: cisplatin
- preferred_term: fluorouracil
term:
id: CHEBI:46345
label: 5-fluorouracil
target_mechanisms:
- target: Adaptive Immune Resistance
treatment_effect: INHIBITS
description: Pembrolizumab targets PD-1 to reverse checkpoint-mediated immune resistance in advanced esophageal carcinoma.
evidence:
- reference: PMID:34454674
reference_title: "Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Compared with placebo plus chemotherapy, pembrolizumab plus \nchemotherapy improved overall survival in patients with previously untreated, \nadvanced oesophageal squamous cell carcinoma and PD-L1 CPS of 10 or more, and \noverall survival and progression-free survival in patients with oesophageal \nsquamous cell carcinoma, PD-L1 CPS of 10 or more, and in all randomised patients \nregardless of histology"
explanation: KEYNOTE-590 establishes first-line pembrolizumab plus chemotherapy as standard of care in advanced esophageal carcinoma.
- name: Adjuvant Nivolumab After Trimodality Therapy
description: >-
In patients with resected esophageal or gastroesophageal junction cancer
who have residual pathologic disease after neoadjuvant chemoradiotherapy,
adjuvant nivolumab significantly prolongs disease-free survival.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: nivolumab
term:
id: NCIT:C68814
label: Nivolumab
target_mechanisms:
- target: Adaptive Immune Resistance
treatment_effect: INHIBITS
description: Adjuvant nivolumab blocks PD-1 to counteract checkpoint-mediated immune resistance in resected high-risk disease.
evidence:
- reference: PMID:33789008
reference_title: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo."
explanation: CheckMate 577 supports adjuvant PD-1 blockade after trimodality therapy as a new standard of care.
- name: Trastuzumab for HER2-Positive EAC
description: >-
HER2-targeted monoclonal antibody therapy is appropriate for the
ERBB2-amplified subset of esophageal/gastroesophageal junction
adenocarcinoma, biomarker-selected by IHC/FISH testing.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: trastuzumab
term:
id: CHEBI:231601
label: trastuzumab
evidence:
- reference: PMID:20728210
reference_title: "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Trastuzumab in combination with chemotherapy can be considered \nas a new standard option for patients with HER2-positive advanced gastric or \ngastro-oesophageal junction cancer."
explanation: ToGA establishes trastuzumab plus chemotherapy as a standard option in HER2-positive advanced gastro-oesophageal junction adenocarcinoma, which overlaps with esophageal adenocarcinoma at the GEJ.
- reference: PMID:28052061
reference_title: Integrated genomic characterization of oesophageal carcinoma.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Squamous cell carcinomas showed frequent genomic amplifications of CCND1 and SOX2 and/or TP63, whereas ERBB2, VEGFA and GATA4 and GATA6 were more commonly amplified in adenocarcinomas."
explanation: Anchors the ERBB2/HER2-amplified EAC subset as the biological rationale for trastuzumab eligibility.
clinical_trials:
- name: NCT03189719
phase: PHASE_III
status: COMPLETED
description: >-
KEYNOTE-590 evaluated pembrolizumab plus fluorouracil-cisplatin versus
chemotherapy alone as first-line treatment for advanced esophageal cancer
and Siewert type 1 gastro-esophageal junction cancer.
evidence:
- reference: PMID:34454674
reference_title: "Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This trial is registered with ClinicalTrials.gov, \nNCT03189719, and is closed to recruitment."
explanation: Establishes NCT03189719 as the pivotal first-line ESCC immunochemotherapy trial.
- name: NCT02743494
phase: PHASE_III
status: COMPLETED
description: >-
CheckMate 577 evaluated adjuvant nivolumab versus placebo in resected
esophageal or gastroesophageal junction cancer with residual pathologic
disease after neoadjuvant chemoradiotherapy.
evidence:
- reference: PMID:33789008
reference_title: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "(Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.)"
explanation: Anchors CheckMate 577 as the pivotal trial supporting adjuvant nivolumab in resected disease.
datasets: []